New Delhi: The Serum Institute of India (SII) has sought emergency use authorisation of its vaccine candidate Covishield in the country.
The Pune-based SII is conducting the India trials of Covishield vaccine developed by AstraZeneca and Oxford University.
In in its application to the the Drug Controller General of India (DCGI), SII cited “unmet medical needs due to the pandemic and in the interest of the public at large” as the reason for seeking emergency authorisation of the vaccine emergency use approval.
Earlier, Pfizer India became the first pharmaceutical firm to seek emergency use authorisation for its COVID-19 vaccine candidate in the country.
Comments are closed.